Mei MG, Chen L, Godfrey J, Song JY, et al. Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade. Blood 2023 Jun 20:blood.2023020485. doi: 10.1182/blood.2023020485.
PMID: 37339586